Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma: a single technology appraisal

Maund, Emma, Cooper, Keith, Takahashi, Marcia Tomie and Shepherd, Jonathan (2022) Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma: a single technology appraisal (Health Technology Assessment, 135558) National Institute for Health and Care Research 86pp.

Record type: Monograph (Project Report)

Abstract

This report is a critique of the company’s submission (CS) to NICE from Roche on the clinical effectiveness and cost effectiveness of polatuzumab [POLIVY®] for treating adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). It identifies the strengths and weaknesses of the CS.

Text

ERG report - polatuzumab - Version of Record

Available under License Other.

Download (2MB)

More information

Published date: September 2022

Related URLs:

https://www.fundingawards.nihr...NIHR135558

Identifiers

Local EPrints ID: 471450

URI: http://eprints.soton.ac.uk/id/eprint/471450

PURE UUID: 06fcd72f-52ef-41ee-91d3-0353cf743be2

ORCID for Emma Maund:

orcid.org/0000-0002-3998-6669

ORCID for Keith Cooper:

orcid.org/0000-0002-0318-7670

ORCID for Marcia Tomie Takahashi:

orcid.org/0000-0002-6932-2660

ORCID for Jonathan Shepherd:

orcid.org/0000-0003-1682-4330

Catalogue record

Date deposited: 08 Nov 2022 18:32

Last modified: 11 Sep 2024 02:31

Export record

Share this record

Share this on Facebook Share this on Twitter Share this on Weibo

Contributors

Author: Emma Maund

Author: Keith Cooper

Author: Marcia Tomie Takahashi

Author: Jonathan Shepherd

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Library staff additional information